FDA grants expanded approval for Lilly's lung cancer drug

Eli Lilly and Co. announced it has secured FDA approval to market Alimta as a first-line treatment in combination with cisplatin, a chemotherapy drug, for advanced and metastatic nonsmall-cell lung cancer. The agency has cleared Alimta for the treatment of a rare type of lung cancer primarily caused by asbestos and as a second-line treatment for lung cancer patients who have received chemotherapy.

View Full Article in:

Indianapolis Star (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC